DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016" report to their offering.
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. Our latest report Interleukin 17A - Pipeline Review, H2 2016, outlays comprehensive information on the Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Interleukin-17A is a protein encoded by the IL17A gene. It acts as a ligand for IL17RA and IL17RC. It is involved in inducing stromal cells to produce proinflammatory and hematopoietic cytokines. High levels of this cytokine are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 2, 4 and 1 respectively.
Furthermore, this report also reviews key players involved in Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.
Key Topics Covered:
- Introduction
- Interleukin 17A Overview
- Therapeutics Development
- Pipeline Products for Interleukin 17A - Overview
- Pipeline Products for Interleukin 17A - Comparative Analysis
- Interleukin 17A - Therapeutics under Development by Companies
- Interleukin 17A - Therapeutics under Investigation by Universities/Institutes
- Interleukin 17A Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Interleukin 17A - Products under Development by Companies
- Interleukin 17A - Products under Investigation by Universities/Institutes
- Interleukin 17A - Companies Involved in Therapeutics Development
- AbbVie Inc
- Abeome Corporation
- Affibody AB
- Cell Medica Limited
- Eli Lilly and Company
- Johnson & Johnson
- Merck KGaA
- Novartis AG
- Orega Biotech SAS
For more information about this report visit http://www.researchandmarkets.com/research/z26mcx/interleukin_17a
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
